Arcturus Therapeutics (ARCT) Tops Q3 EPS by 31c

Arcturus Therapeutics (NASDAQ: ARCT) reported Q3 EPS of ($0.26), $0.31 better than the analyst estimate of ($0.57). Revenue for the quarter came in at $41.67 million versus the consensus estimate of $53.46 million.

For earnings history and earnings-related data on Arcturus Therapeutics (ARCT) click here.

You May Also Be Interested In

• ​Trump said he was unaware of his earnings from crypto
• Trump: 40-60% of chip manufacturing will be in the U.S. - CNBC Interview
• Berenberg Starts Brooks Macdonald Group PLC (BRK:LN) at Buy